分红方面，塞力医疗A股上市后累计派现2707.41万元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，塞力医疗十大流通股东中，财通优势行业轮动混合A（011201） 位居第六大流通股东，持股122.82万股，相比上期增加58.48万股。广发医疗保健股票A（004851）位居 第七大流通股东，持股122.36万股，为新进股东。招商丰韵混合A（006364）位居第九大流通股东，持 股62.40万股，为新进股东。财通科创主题灵活配置混合(LOF)（501085）位居第十大流通股东，持股 56.00万股，为新进股东。 今年以来塞力医疗已经37次登上龙虎榜，最近一次登上龙虎榜为8月26日，当日龙虎榜净买入1.46亿 元；买入总计4.89亿元 ，占总成交额比18.85%；卖出总计3.43亿元 ，占总成交额比13.22%。 资料显示，塞力斯医疗科技集团股份有限公司位于湖北省武汉市东西湖区金山大道1310号，成立日期 2004年2月23日，上市日期2016年10月31日，公司主营业务涉及医疗检验集约化营销及服务业务、体外 诊断产品的代理以及自主体外诊断产品的研发、生产和销售。主营业务收入构成为：IVD ...

资金流向方面，主力资金净流入1522.96万元，特大单买入1516.98万元，占比5.03%，卖出691.85万元， 占比2.29%；大单买入6589.17万元，占比21.83%，卖出5891.33万元，占比19.52%。 12月24日，创新医疗盘中上涨2.04%，截至13:33，报21.49元/股，成交3.02亿元，换手率3.43%，总市值 94.83亿元。 创新医疗今年以来股价涨169.97%，近5个交易日涨4.42%，近20日涨0.14%，近60日涨2.87%。 责任编辑：小浪快报 资料显示，创新医疗管理股份有限公司位于浙江省诸暨市山下湖镇珍珠工业园，成立日期2003年9月30 日，上市日期2007年9月25日，公司主营业务涉及医疗服务。主营业务收入构成为：医疗服务业务 99.73%，其他(补充)0.27%。 创新医疗所属申万行业为：医药生物-医疗服务-医院。所属概念板块包括：小盘、医疗器械、DeepSeek 概念、互联医疗、眼科概念等。 截至9月30日，创新医疗股东户数13.02万，较上期增加58.75%；人均流通股3196股，较上期减少 37.01%。2025年1月-9月，创新医疗实现营业收入5.9 ...

12月23日，三诺生物盘中下跌2.01%，截至13:59，报17.06元/股，成交9273.06万元，换手率1.20%，总 市值95.58亿元。 三诺生物所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、抗原检测、 体外诊断、高血压防治、智慧医疗等。 截至9月30日，三诺生物股东户数2.46万，较上期增加58.52%；人均流通股18347股，较上期减少 37.47%。2025年1月-9月，三诺生物实现营业收入34.53亿元，同比增长8.52%；归母净利润2.11亿元，同 比减少17.36%。 分红方面，三诺生物A股上市后累计派现15.12亿元。近三年，累计派现3.44亿元。 机构持仓方面，截止2025年9月30日，三诺生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股2566.60万股，相比上期增加329.67万股。睿远成长价值混合A（007119）位居第四大流通 股东，持股1832.48万股，相比上期减少873.24万股。华宝中证医疗ETF（512170）位居第六大流通股 东，持股961.42万股，相比上期减少150.68万股。睿远均衡价值三年持有混合A（008969 ...

资料显示，依米康科技集团股份有限公司位于四川省成都高新区科园南二路二号，成立日期2002年9月 12日，上市日期2011年8月3日，公司主营业务涉及数字基础设施全生命周期绿色解决方案服务商,依托 数据中心覆盖全产业链,通过旗下关键设备、智能工程、物联软件、智慧服务四大板块对应数据中心全 生命周期各个节点,提供绿色节能数字中心规划方案、总包建设、关键设备、运维服务等整体解决方案 及服务。主营业务收入构成为：信息数据领域100.00%。 依米康所属申万行业为：计算机-计算机设备-其他计算机设备。所属概念板块包括：百度概念、数字经 济、互联医疗、数字孪生、大数据等。 截至9月30日，依米康股东户数6.27万，较上期增加4.88%；人均流通股5958股，较上期减少4.65%。 2025年1月-9月，依米康实现营业收入10.64亿元，同比增长52.61%；归母净利润2764.72万元，同比增长 273.71%。 12月23日，依米康盘中上涨2.11%，截至10:23，报14.54元/股，成交9173.22万元，换手率1.71%，总市 值64.05亿元。 分红方面，依米康A股上市后累计派现5107.09万元。近三年，累计 ...

泰格医药今年以来股价跌5.51%，近5个交易日涨2.09%，近20日涨3.51%，近60日跌13.66%。 资料显示，杭州泰格医药科技股份有限公司位于浙江省杭州市滨江区西兴街道聚工路19号盛大科技园A 座18层，成立日期2004年12月15日，上市日期2012年8月17日，公司主营业务涉及为国内外医药及健康 相关产品的研究开发提供专业临床研究服务,业务范围主要包括I至IV期临床试验技术服务、数据管理及 统计分析、注册申报、临床试验现场服务、SMO服务、医学检测服务、医学资料翻译、医学影像诊断 服务和培训服务。主营业务收入构成为：临床试验相关服务及实验室服务52.60%，临床试验技术服务 45.21%，其他(补充)2.19%。 12月19日，泰格医药盘中上涨2.03%，截至10:17，报51.33元/股，成交1.95亿元，换手率0.68%，总市值 441.96亿元。 资金流向方面，主力资金净流入594.29万元，特大单买入1725.09万元，占比8.83%，卖出2167.20万元， 占比11.10%；大单买入4843.08万元，占比24.80%，卖出3806.68万元，占比19.50%。 截至9月30日，泰格医 ...

Core Viewpoint - Meinian Health's stock price has shown significant growth this year, with a year-to-date increase of 34.37% and a recent surge of 25.77% over the past five trading days, indicating strong market interest and performance [1]. Financial Performance - For the period from January to September 2025, Meinian Health reported a revenue of 6.925 billion yuan, reflecting a year-on-year decrease of 3.01%. However, the net profit attributable to shareholders was 51.86 million yuan, which represents a substantial year-on-year increase of 110.53% [2]. Stock Market Activity - As of December 19, Meinian Health's stock price reached 6.15 yuan per share, with a trading volume of 2.34 billion yuan and a turnover rate of 9.85%. The total market capitalization stands at 24.073 billion yuan [1]. - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) three times this year, with the most recent appearance on December 18, where it recorded a net buying of 171 million yuan [1]. Shareholder Information - As of September 30, 2025, Meinian Health had 152,000 shareholders, a decrease of 11.85% from the previous period. The average number of circulating shares per person increased by 13.44% to 25,490 shares [2]. - The top ten circulating shareholders include notable ETFs, with Huabao Zhongzheng Medical ETF holding 88.664 million shares, a decrease of 15.1218 million shares from the previous period [3].

12月18日，理邦仪器盘中上涨2.07%，截至09:57，报12.80元/股，成交2231.03万元，换手率0.52%，总 市值74.20亿元。 机构持仓方面，截止2025年9月30日，理邦仪器十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股3386.87万股，相比上期减少309.93万股。医疗器械ETF（159883）位居第九大流通股东， 持股178.76万股，为新进股东。博道远航混合A（007126）位居第十大流通股东，持股167.37万股，为 新进股东。招商量化精选股票发起式A（001917）退出十大流通股东之列。 责任编辑：小浪快报 理邦仪器所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、养老产业、 多胎概念、体外诊断、智慧医疗等。 截至11月28日，理邦仪器股东户数2.30万，较上期减少2.76%；人均流通股14710股，较上期增加 2.83%。2025年1月-9月，理邦仪器实现营业收入14.46亿元，同比增长4.63%；归母净利润2.57亿元，同 比增长49.29%。 分红方面，理邦仪器A股上市后累计派现11.28亿元。近三年，累计派现3.60亿元。 资金流 ...

Group 1 - The core viewpoint of the news is that Zhejiang University Netnew has shown a significant increase in stock price and trading activity, with a year-to-date increase of 48.05% and a recent trading volume of 2.29 billion yuan [1] - As of September 30, 2025, Zhejiang University Netnew reported a revenue of 2.389 billion yuan, representing a year-on-year growth of 3.89%, and a net profit attributable to shareholders of 31.1936 million yuan, which is a substantial increase of 162.90% [2] - The company has a diverse revenue structure, with the main business segments being industrial digitalization (64.26%), government digitalization (13.59%), infrastructure digitalization (10.98%), and intelligent cloud services (9.54%) [1] Group 2 - The company has been actively participating in various concept sectors, including intellectual property, smart governance, internet healthcare, ChatGPT concepts, and facial recognition [2] - As of September 30, 2025, the number of shareholders increased to 211,700, reflecting a growth of 13.37%, while the average circulating shares per person decreased by 11.79% to 4,853 shares [2] - The company has distributed a total of 460 million yuan in dividends since its A-share listing, with 71.9268 million yuan distributed over the past three years [3]

Core Viewpoint - Anke Biological has experienced a decline in stock price recently, with a year-to-date increase of 15% but a notable drop in the last 20 and 60 days [1][2] Financial Performance - For the period from January to September 2025, Anke Biological reported a revenue of 1.963 billion yuan, representing a year-on-year growth of 2.15%. However, the net profit attributable to shareholders decreased by 6.48% to 551 million yuan [2] - The company has distributed a total of 2.662 billion yuan in dividends since its A-share listing, with 1.252 billion yuan distributed in the last three years [3] Stock Market Activity - As of December 3, Anke Biological's stock price was 9.65 yuan per share, with a market capitalization of 16.14 billion yuan. The stock has seen a trading volume of 155 million yuan and a turnover rate of 1.31% [1] - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with a net purchase of 193 million yuan on July 31 [1] Shareholder Information - As of November 10, the number of shareholders for Anke Biological was 76,100, a decrease of 1.10% from the previous period. The average number of circulating shares per shareholder increased by 1.11% to 16,062 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several investment funds, with notable changes in their holdings [3]

Core Viewpoint - The stock of Lifesense Instruments has shown a positive trend, with a year-to-date increase of 27.68% and a market capitalization of 8.121 billion yuan as of November 27 [1]. Financial Performance - For the period from January to September 2025, Lifesense Instruments reported a revenue of 1.446 billion yuan, representing a year-on-year growth of 4.63%. The net profit attributable to shareholders was 257 million yuan, marking a significant increase of 49.29% compared to the previous year [2]. Shareholder Information - As of November 10, 2025, the number of shareholders for Lifesense Instruments was 23,500, a decrease of 3.61% from the previous period. The average number of tradable shares per person increased by 3.74% to 14,407 shares [2]. - The company has distributed a total of 1.128 billion yuan in dividends since its A-share listing, with 360 million yuan distributed over the past three years [3]. Stock Market Activity - On November 27, 2025, Lifesense Instruments experienced a stock price increase of 2.04%, reaching 14.01 yuan per share, with a trading volume of 75.793 million yuan and a turnover rate of 1.63% [1]. - The net inflow of main funds was 5.928 million yuan, with significant buying activity from large orders [1]. Business Overview - Lifesense Instruments, established on August 2, 1995, and listed on April 21, 2011, specializes in the research, production, sales, and service of medical electronic devices and in vitro diagnostic products. The main revenue sources include patient monitoring (29.38%), in vitro diagnostics (20.94%), ultrasound imaging (16.26%), maternal and child health (15.36%), and electrocardiogram diagnostics (15.25%) [1].